ONB, Stifel and Danaher Deliver Q3 Earnings Beats Across Banking, Wealth Management and Life Sciences

• Old National Bancorp (ONB) beat Q3 EPS on net interest margin resilience and disciplined Midwest loan growth
• Stifel Financial (SF) beat Q3 EPS at $1.82 with recovering investment banking fees, trading at 5.8% discount to GF fair value
• Danaher (DHR) beat EPS estimates and raised full-year guidance on bioprocessing and diagnostics recovery

Three Q3 earnings beats across Old National Bancorp, Stifel Financial and Danaher in a single reporting cycle present a coherent picture: the US corporate earnings season is running ahead of consensus across regional banking, investment banking and life sciences equipment. ONB's beat — a regional bank with deep exposure to the US Midwest industrial corridor — suggests that credit quality remains stable and that anticipated commercial loan stress from higher-for-longer rates has been more gradual than feared.

Stifel's beat deserves special attention because the investment banking cycle is typically a lagging indicator of broader deal activity. Stifel is a mid-market investment bank with strength in municipal bonds, institutional equity research and wealth management. Its Q3 outperformance, combined with recovering investment banking fees, suggests that mid-market M&A and IPO activity is reaccelerating — a positive leading indicator for deal flow in Q4 2026 and H1 2027.

Danaher's guidance raise is the most market-moving signal among the three. Danaher's life sciences instruments segment is the clearest leading indicator of pharmaceutical and biotech R&D spending. When DHR raises guidance, it signals that biopharma customers are accelerating capital deployment plans. This is a positive read-through for the broader biotech sector, CROs and clinical research infrastructure providers.

Synthesised from 3 sources: GuruFocus (ONB), GuruFocus (SF), GuruFocus (DHR)